The Recombinant Cell Culture Supplements Market Size is valued at 388.35 million in 2023 and is predicted to reach 1008.85 million by the year 2031 at a 12.75% CAGR during the forecast period for 2024-2031.
Rising demand for cell culture supplements, increased mergers and acquisitions to diversify the portfolio of recombinant cell culture supplements, and increased funding for biopharmaceutical product research and development in the life sciences sector are some factors boosting market growth. Other factors boosting market growth include rising demand for stem cell and regenerative medicine research, immunotherapy, and the need for animal-free supplements in cell culture applications. Regulatory bodies are also pushing for the use of animal-free media supplements in cell culture processes. The growth is anticipated to be inhibited by the high cost, the technical difficulties related to recombinant cell culture supplements, and the shortage of qualified personnel.
Competitive Landscape:
Some of the recombinant cell culture supplements market players are:
- Abcam plc.
- Corning Incorporated
- Lonza Group AG
- Merck KGaA
- Sartorius AG
- Thermo Fisher Scientific Inc.
- BBI Solutions
- FUJIFILM Irvine Scientific Inc.
- Gemini Bioproducts LLC
- HiMedia Laboratories
- InVitria, Kingfisher Biotech
- Novus Biologicals LLC
- R&D Systems
- Sino Biological Inc.
- STEMCELL Technologies Inc
Market Segmentation:
The recombinant cell culture supplements Market is segmented on the basis of product, application, and expression system. Product segment includes recombinant albumin (rAlbumin), recombinant insulin (rInsulin), recombinant epidermal growth factor (rEGF), recombinant interleukin growth factor (rILGF), recombinant transferrin (rTransferrin), recombinant trypsin (rTrypsin), recombinant Insulin-like growth factor (rIGF), recombinant stem cell factor (rSCF), recombinant aprotinin (rAprotinin), recombinant lysozyme (rLysozyme), and others. Application segment includes stem cell and regenerative medicine, Bio-Production, and academic and research application. The expression system segment includes Mammalian, E. Coli, Yeast, and others.
Based On Application, The Stem Cell And Regenerative Medicine Segment Is Accounted As A Major Contributor In The Recombinant Cell Culture Supplements.
Stem cell and regenerative medicine held a commanding market share in 2023, leading the global market for recombinant cell culture supplements (by application). But due to improved cell viability and batch-to-batch uniformity of final products, academic and research applications are identified to be the fastest expanding segment over the forecast period.
Mammalian Expression System Segment Witnessed Growth At A Rapid Rate
With a significant market share in 2023, the mammalian expression system dominated the recombinant cell culture supplements market. Stable cell lines produced from mammalian cells are used by the majority of biopharmaceutical businesses in the world to produce biologics.
North America Dominated The Market For Additives To Recombinant Cell Culture In The Region
In 2023, North America dominated the market for supplements used in recombinant cell cultures. The expansion can be linked to the region's inclusion of essential players as well as the accessibility of money and technology for recombinant cell culture supplements.
Recombinant Cell Culture Supplements Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2023 |
USD 388.35 Mn |
|
Revenue forecast in 2031 |
USD 1008.85 Mn |
|
Growth rate CAGR |
CAGR of 12.75% from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Product, Application, And Expression System |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Abcam plc., Corning Incorporated, Lonza Group AG, Merck KGaA, Sartorius AG, and Thermo Fisher Scientific Inc., BBI Solutions, FUJIFILM Irvine Scientific, Inc., Gemini Bioproducts, LLC, HiMedia Laboratories, InVitria, Kingfisher Biotech, Inc., Novus Biologicals, LLC, R&D Systems, Inc., Sino Biological Inc., and STEMCELL Technologies Inc. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
